Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel polymer micelles + gemcitabine + lenvatinib
- Development stage
- Unknown
- Lead developer
- Shanghai Sixth People’s Hospital
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy regimen consists of a novel nanoparticle formulation of paclitaxel (polymer micelles), the antimetabolite gemcitabine, and the multi-kinase inhibitor lenvatinib. It is being investigated by Shanghai 6th People's Hospital in the Phase 2 MAGNATE-S trial for the treatment of advanced, unresectable, or metastatic bone sarcomas that have progressed after first-line therapy. Paclitaxel polymer micelles are designed to improve solubility and reduce hypersensitivity reactions compared to traditional paclitaxel. Gemcitabine inhibits DNA synthesis by acting as a nucleoside analog, while lenvatinib targets multiple tyrosine kinases including VEGFR1-3, FGFR1-4, PDGFRα, KIT, and RET to inhibit angiogenesis and tumor cell proliferation. In the MAGNATE-S study, this specific combination is primarily allocated to patients with bone sarcoma, while a similar regimen substituting lenvatinib with anlotinib is used for soft tissue sarcoma.
- Other names
- Paclitaxel Micelles + Gemcitabine + Lenvatinib
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)TUBB (Tubulin (alpha and beta subunits))RNR (Ribonucleotide reductase)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)DNA replication machinery / nascent DNAFGFR3 (Fibroblast growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on paclitaxel polymer micelles + gemcitabine + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel polymer micelles + gemcitabine + lenvatinib.